
Maddie Meyer/Getty Images News
Moderna (NASDAQ:MRNA) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its Spikevax COVID-19 vaccine to allow its use in children as young as six months.
Clearing the company’s supplemental Biologics License Application